Microbiotix announces exclusive Worldwide licensing Agreement for HCV NS5B Non-Nucleoside Polymerase Inhibitor

Date: Jan 02, 2013
Source: ( click here to go to the source)

Featured firm in this article: Microbiotix Inc of Worcester, MA

02272026	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy Avidity Biosciences Inc (1 awards)
08052025	Quantum Copper Wins 2025 Dick Burdick Innovation Award for Breakthrough Fire Retardant Polymer Technology Quantum Copper Inc (1 awards)
11142024	TFF Pharmaceuticals Announces It Will Wind Down Operations TFF Pharmaceuticals Inc (1 awards)
10302024	Opus Genetics acquired, becomes public company based in NC Opus Genetics Inc (1 awards)
04032024	Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement Kintara Therapeutics Inc (1 awards)
11132023	Selecta Biosciences Announces Merger with Cartesian Therapeutics Cartesian Therapeutics Inc (5 awards)
09252023	AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics AcuraStem Inc (5 awards)
08222023	Grander Closes Acquisition of PolarityTE, Inc. Assets PolarityTE Inc (1 awards)
08082023	Alchemist Completes Acquisition of Aqueous Resources LLC, a Leader in Industrial Brine Pre-Treatment Solutions and Direct Lithium Extraction Aqueous Resources LLC (1 awards)
08082023	Arcfield Acquires Strategic Technology Consulting Strategic Technology Consulting LLC (1 awards)

News Article